Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd International Conference on Molecular Medicine and Diagnostics Dubai,UAE.

Day 1 :

OMICS International Molecular Medicine 2018 International Conference Keynote Speaker Hildegund C.J. Ertl photo
Biography:

Hildegund C.J. Ertl, Professor in Wistar Institute, Philadelphia, PA and Associate Professor of Pathology and Laboratory Medicine, Associate Faculty of the School of Medicine, University of Pennsylvania, Philadelphia, PA Program Director, Immunology Program, The Wistar Institute, Philadelphia, PA, Adjunct Professor of Pediatrics of the Children’s Hospital of Philadelphia, Director, Wistar Vaccine Center and World Health Organization (WHO) Reference Center for Reference and Research on Rabies
 

Abstract:

Recent years have shown tremendous progress in active immunotherapy of cancers through tumor antigen (TA)-specific vaccines, adoptive T cell transfer or check point inhibitors. Nevertheless complete cures remain rare. TA-specific CD8+ T cells rapidly become exhausted once they enter solid tumors. This exhaustion, causing loss of tumor infiltrating CD8+ T cells during tumor progression, is in part cause by metabolic constrains, such as hypoxia and hypoglycemia, within the tumor microenvironment (TME). Lack of glucose forces T cells to switch from glycolysis for energy and biomass production to fatty acid catabolism. Most T cells are apparently unable to adjust their metabolism within the TME and as a consequence loose functions and eventually die. Pre-conditioning T cells during their initial activation in lymphatic tissues or their expansion in vitro towards fatty acid beta oxidation (FAO) preserves their functions and allows them to more effectively reduce tumor burden. CD8+ T cell metabolism can be modified by different types of manipulations such as knockdown of HIF-1a or other key factors of the glycolysis pathway to reduce the cells’ reliance on glucose. FAO can be enhanced directly by strengthening signaling through PPAR-a, the master regulator of lipid metabolism.  

OMICS International Molecular Medicine 2018 International Conference Keynote Speaker Jan O. Gordeladze photo
Biography:

Dr. Jan O. Gordeladze, PhD (born 25th of April, 1950), holds a triple professor competence (medical biochemistry, physiology, and pharmacology), and is presently working as a professor at the Department of Biochemistry, Institute of Basic Medical Science, University of Oslo, Norway. He has previously been employed as the medical director of MSD, Norway, serving two years as a Fulbright scholar at the NIH, Bethesda, Maryland, USA, and from 2006-2009 also being employed as associate professor at the University of Montpellier, France. He is a member of the Norwegian Stem Cell Center, and his research has over the past 7-10 years been devoted to differentiation of osteochondral cells from stem cells focusing on the impact of transcription factors and microRNA species constituting regulatory loop interactions with functional target genes. He has published more than 120 scientific articles, reviews/book chapters and presented more than 250 abstracts/posters/talks at conferences world wide. Dr. Gordeladze has served as a Fulbright Scholar at the National Institute of Health, Bethesda, Washington DC during the years 1990-91.

Abstract:

To be updated

Break: Group Photo and Refreshment Break: 11:00-11:15
OMICS International Molecular Medicine 2018 International Conference Keynote Speaker Joel I. Osorio photo
Biography:

CEO & Founder - Biotechnology and Regenerative Medicine at RegenerAge International (www.regenerage.clinic ). VP of International Clinical Development for Bioquark, Inc. (www.bioquark.com). Chief Clinical Officer at ReAnima Advanced
Biosciences (www.reanima.tech). Westhill University School of Medicine. Mexico Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine (A4M). Visiting scholar at University of North Carolina at Chapel Hill (Dermatology) Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida.
 

 

Abstract:

As it has been previously demonstrated that coelectroporation of Xenopus laevis frog oocytes with normal cells and cancerous cell lines induces the expression of pluripotency markers, and in experimental murine model studies that mRNA extract (Bioquantine purified from intra-and extra-oocyte liquid phases of electroporated
oocytes) showed potential as a treatment for a wide range of conditions as Squint, Spinal Cord Injury (SCI) and Cerebral Palsy among others. The current study observed beneficial changes with Bioquantine administration in a patient with a severe SCI. Pluripotent stem cells have therapeutic and regenerative potential in clinical situations CNS disorders even cancer.2-3-7 One method of reprogramming somatic cells into pluripotent stem cells is to expose them to extracts prepared from Xenopus laevis oocytes1 We showed previously that coelectroporation of Xenopus laevis frog oocytes; with normal cells and cancerous cells lines, induces expression of markers of pluripotency.4 We also observed therapeutic effects of treatment with a purified extract (Bioquantine) of intra- and extra-oocyte liquid phases derived from electroporated X. laevis oocytes, on experimentally induced pathologies including murine models of melanoma, traumatic brain injury, and experimental skin wrinkling induced by squalenemonohydroperoxide.The positive human findings for Spinal Cord Injury, and Cerebral Palsy with the results from previous animal studies with experimental models of traumatic brain injury, respectively (Paylian et al, 2016). Because of ethical reasons, legal restrictions, and a limited number of patients, we were able to treat only a very small number of patients. These results indicate that Bioquantine may be safe and well tolerated for use in humans and deserves further study in a range of degenerative disorders. We propose that the mechanism of action of Bioquantine in these various diseases derives from its unique pharmacology and combinatorial reprogramming properties. In conclusion, these preliminary findings suggest that Bioquantine is safe and well tolerated on patients with Cerebral Palsy and- Spinal Cord Injury, among others. In addition to the regenerative therapy and due to the patient condition, we decided to include the Restore- Sensor SureScan5-6. Based on the of electrical stimulation for rehabilitation and regeneration after spinal cord injury published by Hamid and MacEwan 8-9, we designed an improved delivery method for the in-situ application of MSCs and Bioquantine in combination with the Restore Sensor Sure Scan Conclusions: To the present day the patient who suffered a total section of spinal cord at T12-L1 shows an improvement in sensitivity, strength in striated muscle and smooth muscle connection, 11 months after the first therapy of cell regeneration and 3 month after the placement of Restore Sensor  at the level of the lesion, the patient with a complete medullary section shows an evident improvement on his therapy of physical rehabilitation on crawling from front to back by himself and standing on his feet for the first time and showing a progressively important functionality on the gluteal and legs sensitivity110-11
Reference:
1. Sergei Paylian, et al., Potential Threapeutic Applications of Extract Made from Electroporated Xenopus Laevis frog Oocytes in
Murine Models of Melanoma, Traumatic Brain Injury and Experimental Skin Wrinkling BAOJPharmSci2016,2:2 2:024.
2. Kim JS, Choi HW, Choi S, Do JT. Reprogrammed pluripotent stem cells from somatic cells. Int J Stem Cells. Jun 2011;4(1):1-8.
3. Kim WH, Shen H, Jung DW, Williams DR. Some leopards can change their spots: potential repositioning of stem cell reprogramming compounds as anti-cancer agents. Cell Bio Toxicol. Jun 2016;32(3):157-168.
4. Paylian S. Co-electroporation with Xenopus laevis oocytes reprograms normal and cancerous human cells to resembel induced human pluripotent stem cells. BAOJ Cancer Res Ther. 2015;1:1-13.
5. Using neurostimulation for chronic pain Medtronic, Inc. 2016 All Rights Reserved M940100A007 Rev A 6. RestoreSensor® SureScan® MRI 97714 Rechargeable neurostimulator © Medtronic,
Inc. 2016 All Rights Reserved M940100A007 Rev A
7. Cell Transplant. 2014;23(4-5):573-611. doi: 10.3727/096368914X678427. Spinal cord regeneration. Young W.
8. Eur Spine J. 2008 Sep; 17(9): 1256–1269. Published online 2008 Aug 2. doi: 10.1007/s00586-008-0729-3 Role of electrical stimulation for rehabilitation and regeneration after spinal cord injury: an overview. Samar Hamid corresponding author and Ray Hayek
9. Front Neurosci. 2016; 10: 557. Published online 2016 Dec 8. doi: 10.3389/fnins. 2016.00557 Regenerated Sciatic Nerve Axons
Stimulated through a Chronically Implanted Macro-Sieve Electrode. Matthew R. MacEwan, Erik R. Zellmer, Jesse J. Wheeler,
Harold Burton, and Daniel W. Moran.
10. RegenerAge System: erapeutic E ects of Combinatorial Biologics (Bioquantine®) and Spinal Cord Stimulation System on a
Patient with Spinal Cord Section Nov 30, 2017 Med Clin Res, 2017. Vol 2 | Issue 4 | 1 of 1
11. Therapeutic Effects of Bioquantine® in Patients diagnosed with Squint (extropia), Cerebral Palsy, Spinal Cord Injuries, Skin
Rejuvenation and Regeneration”. Joel I. Osorio, J Tissue Sci Eng 2017, 8:2 (Suppl) DOI: 10.4172/2157-7552-C1_033